RecruitingPhase 2NCT03503331

UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy

Sponsor

University of Alabama at Birmingham

Enrollment

160 participants

Start Date

Apr 20, 2018

Study Type

INTERVENTIONAL

Conditions

Alzheimer Disease

Summary

The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer \[C-11\]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with \[C-11\]PiB-PET, and cognitive status will be the primary outcome of this imaging study.

Eligibility

Min Age: 50 Years

Inclusion Criteria2

\- 1. Enrollment in the UAB-ADC study under a separate IRB-approved research protocol (IRB-300000169).
\. Negative urine or serum B-hCG test within 2 days of \[C-11\]PiB administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing.

Exclusion Criteria2

Inability or contraindication for undergoing MRI and/or PET imaging
Inability to participate in the imaging studies due to severity of dementia

Interventions

DRUG[C-11]PiB-PET/MRI

All study participants will undergo brain imaging with \[C-11\]PiB-PET/MRI. \[C-11\]PiB is a PET imaging agent used primarily to measure the amount of abnormal protein (called beta-amyloid) in the brain. The investigator will also use this tracer to evaluate regional cerebral blood flow.